Outgunning mCRPC with SYNC-T Available to Purchase

SYNC-T, an investigational approach combining in situ vaccination, via partial tumor cryolysis, with intratumoral delivery of a cocktail of four immunotherapy agents, appears highly effective in patients with metastatic castration-resistant prostate cancer. Despite this disease being immunologically “cold,” complete responses to SYNC-T were seen in more than half of the patients on a small initial study, and side effects were mild.